Hong Zhao

Also affiliated with Guizhou University, Dalian University of Technology, Methodist Hospital, Shanghai University of Traditional Chinese Medicine, Dalian Municipal Central Hospital, Methodist Hospital, Cipher Gene (China), Ocean University of China, Xi'an Jiaotong University

Materials ScienceBiochemistry, Genetics and Molecular BiologyChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy”.

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Journal of Clinical Oncology(2024)10.1200/jco.24.00546

N/A

0.584DataRank · unranked

15 citations

Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera +13 more

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3074

N/A

0DataRank · unranked

309 citations

Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao +11 more

Site-Specific Immune and Stromal Architecture Drive Resistance to Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.23.654950

N/A

0DataRank · unranked

2 citations

Matthew Vasquez, Jeffrey Zhang, Wei Yang, Yuan Gao, Xiaoxian Li +3 more